Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line endocrine therapy followed by capecitabine versus capecitabine followed by endocrine therapy in metastatic ER-positive breast cancer
2007-007030-20Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tamoxifen, anastrozole, letrozole, exemestane and capecitabine in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Quality of life during time on study and Time to second progression. Started Dec 2007; status: active.
02
Drugs
tamoxifenanastrozoleletrozoleexemestanecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-007030-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007030-20.